Actively Recruiting
Prospective Real-World Study of Fixed-Duration Ibrutinib Plus Venetoclax as First-Line Treatment for Chronic Lymphocytic Leukemia
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
60
Participants Needed
1
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well the combination of Ibrutinib and Venetoclax IV works as a first-line treatment for people with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL in routine medical care. This observational study collects data on patients treated with fixed-duration IV under normal clinical practice, without administering any drugs as part of the study itself. Participants with a confirmed diagnosis of CLL or SLL who require first-line treatment according to international guidelines and who have been prescribed fixed-duration IV independently of the study will be included. No study drugs are given by the researchers instead, the study gathers data from routine clinical care and records patient outcomes related to this treatment approach. During the study, participants health and disease responses will be monitored using data collected during standard care visits up to approximately 60 weeks and for some outcomes up to 4 years. Researchers will review overall response rates, duration of response, progression-free survival, overall survival, treatment tolerability, quality of life questionnaires, adverse events, hospitalization details, and healthcare utilization such as emergency room visits.
CONDITIONS
Brief Title
A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here